(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
EU states agree first step for Ukraine reparations fund- 23 Most Amusing Messages At any point Sent Among Kids and Their Folks
- 2 new malaria treatments announced as drug resistance grows
- Climate change is straining Alaska's Arctic. A new mining road may push the region past the brink
- All that You Really want to Be aware of Dental Inserts Facilities
- CDC clarifies stance on vaccines and autism, stating no evidence supports the link
- Fundamental Home Machines: An Easy to understand Determination Guide
- 'Hero' who wrestled gun from Bondi shooter named as Ahmed al Ahmed
- NASA says Maven spacecraft that was orbiting Mars has gone silent
